RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Autosomal Dominant Polycystic Kidney Disease: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Perioperative complications in native nephrectomy as a therapeutic approach for symptomatic polycystic kidney disease: a comprehensive study.
Helal Birjandi Alireza et al., International urology and nephrology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42012776/
- 2.
Cystic burden meets blood pressure: cardiac remodelling in paediatric autosomal dominant polycystic kidney disease.
Heming Camille et al., Pediatric nephrology (Berlin, Germany) (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42151644/
- 3.
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.
Joly Dominique et al., Kidney international (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42320793/
- 4.
Diagnosing Mendelian Kidney Disease: Hidden Niches in the (Kidney) Genome.
Ekici Arif B et al., American journal of kidney diseases : the official journal of the National Kidney Foundation (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42497974/
- 5.
Papillary Hyperplasia in Autosomal Dominant Polycystic Kidney Disease: A Multi-Institutional Study With Immunohistochemical and Molecular Characterization.
Tanaka Kara S et al., The American journal of surgical pathology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42548188/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558 · Recruiting · Phase 2 · Calico Life Sciences LLC
Ages 18 to 55
https://clinicaltrials.gov/study/NCT06902558
- 2.
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
NCT06714006 · Recruiting · Phase 1 · PYC Therapeutics
Ages 18 to 65
https://clinicaltrials.gov/study/NCT06714006
- 3.
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
NCT04939935 · Recruiting · Phase 3 · The University of Queensland
Ages 18 to 70
https://clinicaltrials.gov/study/NCT04939935
- 4.
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
NCT05401409 · Completed · Na · Western Sydney Local Health District
Ages 18 and over
https://clinicaltrials.gov/study/NCT05401409
- 5.
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
NCT02251275 · Completed · Phase 3 · Otsuka Pharmaceutical Development & Commercialization, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT02251275
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, causing fluid-filled cysts to grow in the kidneys over decades and often leading to kidney failure. It affects approximately 25,000 Australians. The first disease-modifying treatment (tolvaptan) is now available, and research into additional therapies is progressing rapidly.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
PURPOSE: To assess perioperative complications after native nephrectomy in autosomal dominant polycystic kidney disease (ADPKD), identify risk factors and evaluate surgical timing and approach. METHODS: We retrospectively analyzed 124 nephrectomy episodes in patients with ADPKD treated at a single tertiary center between October 2012 and October 2022. Complications were graded according to the Clavien-Dindo classification. Multivariable logistic regression was used to assess predictors of overall and major complications. RESULTS: Perioperative complications occurred in 73/124 episodes (58.9%), including 31 major complications (25.0%). Lower preoperative hemoglobin independently predicted overall complications (OR 0.74 per g/dL, 95% CI 0.61-0.89; p = 0.002), whereas left-sided nephrectomy was associated with a lower overall complication risk (OR 0.25, 95% CI 0.09-0.72; p = 0.011). Diverticulosis independently predicted major complications (OR 5.03, 95% CI 1.76-14.33; p = 0.003). Simultaneous bilateral nephrectomy showed the highest overall complication rate (69.7%). Open procedures were performed for markedly larger kidneys than minimally invasive procedures (median operative specimen weight 3518.5 g vs 495.5 g; p < 0.001). Minimally invasive surgery was not independently associated with a lower complication risk (OR 0.75, 95% CI 0.15-3.79; p = 0.726). CONCLUSION: Native nephrectomy in ADPKD is associated with substantial perioperative morbidity and should remain restricted to carefully selected patients. Surgical timing relative to transplantation should be guided primarily by symptoms and clinical necessity. Simultaneous bilateral nephrectomy appears to carry the greatest perioperative burden. Although minimally invasive surgery is feasible in selected patients with smaller kidneys, our data do not demonstrate an independent reduction in morbidity after adjustment for case complexity.
Common Questions
What is Autosomal Dominant Polycystic Kidney Disease?
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, causing fluid-filled cysts to grow in the kidneys over decades and often leading to kidney failure. It affects approximately 25,000 Australians. The first disease-modifying treatment (tolvaptan) is now available, and research into additional therapies is progressing rapidly.
How many clinical trials are available for Autosomal Dominant Polycystic Kidney Disease?
RareWays currently indexes 88 clinical trials for Autosomal Dominant Polycystic Kidney Disease, of which 14 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Autosomal Dominant Polycystic Kidney Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Autosomal Dominant Polycystic Kidney Disease.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.